A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects

A Pilot, Double-blind, Placebo-controlled, Randomized Clinical Trial of mRNA-transfected Autologous Dendritic Cells in Subjects With Well-controlled Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy

The purpose of the study is to find out whether an experimental autologous dendritic cell vaccine is safe, well tolerated, and whether it can strengthen the immune system's response to HIV.

This is a randomized trial to evaluate whether mRNA-transfected dendritic cell vaccination is safe and immunogenic in HIV-infected participants who are on antiretroviral therapy.

Inclusion Criteria:

• HIV-1 positive
• CD4+ T Cell count >200
• Undetectable HIV viral load for 6 months prior to screening
• On antiretroviral treatment for 12 months prior to screening

Exclusion Criteria:

• Hepatitis C positive
• Detectable HIV viral load within 6 months prior to study entry
• Females who are pregnant or nursing